These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 22033801)

  • 1. A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease.
    S Schneider L
    Dialogues Clin Neurosci; 2000 Jun; 2(2):111-28. PubMed ID: 22033801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP
    CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
    Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM
    Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
    Jann MW; Shirley KL; Small GW
    Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
    Rakonczay Z
    Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
    Emre M
    Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F
    Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).
    McHardy SF; Wang HL; McCowen SV; Valdez MC
    Expert Opin Ther Pat; 2017 Apr; 27(4):455-476. PubMed ID: 27967267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.
    Grossberg GT
    Curr Ther Res Clin Exp; 2003 Apr; 64(4):216-35. PubMed ID: 24944370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
    Sharma P; Tripathi MK; Shrivastava SK
    Methods Mol Biol; 2020; 2089():257-286. PubMed ID: 31773661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.